Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

References

• Small D, Levenstein M, Burrow C, Amin S, Civin C I. STK-1 is expressed in a subpopulation of human bone marrow enriched for CD34+ progenitor/stem cells and in a number of leukemic cell lines. Blood 1992; 80: 296a
   Google Scholar
• Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91: 459–463
   PubMed Web of Science ®Google Scholar
• Gu J, Gu X. Natural history and functional divergence of protein tyrosine kinases. Gene 2003; 317: 49–57
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. FLT3: it does matter in leukemia. Leukemia 2003; 17: 1738–1752
   PubMed Web of Science ®Google Scholar
• Hubbard S R. Theme and variations: juxtamembrane regulation of receptor protein kinases. Mol Cell 2001; 8: 481–482
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004; 13: 169–178
   PubMed Web of Science ®Google Scholar
• Dosil M, Wang S, Lemischka I R. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993; 13: 6572–6585
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring H J, deLapeyriere O, Beslu N, Lavagna C, Marchetto S, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol 1996; 95: 218–223
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301–310
   PubMed Web of Science ®Google Scholar
• Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem 1998; 273: 14962–14967
   PubMed Web of Science ®Google Scholar
• Zhang S, Mantel C, Broxmeyer H E. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leuk Biol 1999; 65: 372–380
   PubMed Web of Science ®Google Scholar
• Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg J P, et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 1999; 13: 1374–1382
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719–728
   PubMed Web of Science ®Google Scholar
• Scheijen B, Ngo H T, Kang H, Griffin J D. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004; 23: 3338–3349
   PubMed Web of Science ®Google Scholar
• Kim K T, Baird K, Ahn J Y, Meltzer P, Lilly M, Levis M, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005; 105: 1759–1767
   PubMed Web of Science ®Google Scholar
• Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164–3173
   PubMed Web of Science ®Google Scholar
• Gotze K S, Ramirez M, Tabor K, Small D, Matthews W, Civin C I. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 1998; 91: 1947–1958
   PubMed Web of Science ®Google Scholar
• Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan J F, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643–648
   PubMed Web of Science ®Google Scholar
• Lyman S D, James L, Johnson L, Brasel K, de Vries P, Escobar S S, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83: 2795–2801
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin J D, Moore K A, Boast S, Goff S P, Lemischka I R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147–161
   PubMed Web of Science ®Google Scholar
• McKenna H J, Stocking K L, Miller R E, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489–3497
   PubMed Web of Science ®Google Scholar
• Ray R J, Paige C J, Furlonger C, Lyman S D, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996; 26: 1504–1510
   PubMed Web of Science ®Google Scholar
• Veiby O P, Jacobsen F W, Cui L, Lyman S D, Jacobsen S E. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol 1996; 157: 2953–2960
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Lu L, Cooper S, Ruggieri L, Li Z H, Lyman S D. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995; 23: 1121–1129
   PubMed Web of Science ®Google Scholar
• Hirayama F, Lyman S D, Clark S C, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85: 1762–1768
   PubMed Web of Science ®Google Scholar
• Nicholls S E, Winter S, Mottram R, Miyan J A, Whetton A D. Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. Exp Hematol 1999; 27: 663–672
   PubMed Web of Science ®Google Scholar
• Sitnicka E, Buza-Vidas N, Larsson S, Nygren J M, Liuba K, Jacobsen S E. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003; 102: 881–886
   PubMed Web of Science ®Google Scholar
• Meierhoff G, Dehmel U, Gruss H J, Rosnet O, Birnbaum D, Quentmeier H, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 1995; 9: 1368–1372
   PubMed Web of Science ®Google Scholar
• Drexler H G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588–599
   PubMed Web of Science ®Google Scholar
• Carow C E, Levenstein M, Kaufmann S H, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089–1096
   PubMed Web of Science ®Google Scholar
• Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque M J, Marchetto S, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584–2593
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring H J, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238–248
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–1337
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002; 21: 2555–2563
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434–2439
   PubMed Web of Science ®Google Scholar
• Abu-Duhier F M, Goodeve A C, Wilson G A, Care R S, Peake I R, Reilly J T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983–988
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080
   PubMed Web of Science ®Google Scholar
• Rombouts W J, Blokland I, Lowenberg B, Ploemacher R E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675–683
   PubMed Web of Science ®Google Scholar
• Abu-Duhier F M, Goodeve A C, Wilson G A, Gari M A, Peake I R, Rees D C, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190–195
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Kopecky K J, Meshinchi S, Appelbaum F R, Slovak M L, Willman C L, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589–3595
   PubMed Web of Science ®Google Scholar
• Kottaridis P D, Gale R E, Frew M E, Harrison G, Langabeer S E, Belton A A, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759
   PubMed Web of Science ®Google Scholar
• Whitman S P, Archer K J, Feng L, Baldus C, Becknell B, Carlson B D, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233–7239
   PubMed Web of Science ®Google Scholar
• Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38–43
   PubMed Web of Science ®Google Scholar
• Xu F, Taki T, Yang H W, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol 1999; 105: 155–162
   PubMed Web of Science ®Google Scholar
• Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999; 33: 525–529
   PubMedGoogle Scholar
• Meshinchi S, Woods W G, Stirewalt D L, Sweetser D A, Buckley J D, Tjoa T K, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89–94
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66
   PubMed Web of Science ®Google Scholar
• Boissel N, Cayuela J M, Preudhomme C, Thomas X, Grardel N, Fund X, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699–1704
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005; 82: 100–107
   PubMed Web of Science ®Google Scholar
• Levis M, Allebach J, Tse K F, Zheng R, Baldwin B R, Smith B D, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885–3891
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly L M, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433–443
   PubMed Web of Science ®Google Scholar
• O'Farrell A M, Abrams T J, Yuen H A, Ngai T J, Louie S G, Yee K W, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–3605
   PubMed Web of Science ®Google Scholar
• Yee K W, O'Farrell A M, Smolich B D, Cherrington J M, McMahon G, Wait C L, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941–2949
   PubMed Web of Science ®Google Scholar
• Kelly L M, Yu J C, Boulton C L, Apatira M, Li J, Sullivan C M, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421–432
   PubMed Web of Science ®Google Scholar
• Levis M, Tse K F, Smith B D, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885–887
   PubMed Web of Science ®Google Scholar
• Tse K F, Novelli E, Civin C I, Bohmer F D, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001–1010
   PubMed Web of Science ®Google Scholar
• Patyna S, Laird A D, Mendel D B, O'Farrell A M, Liang C, Guan H, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006; 5: 1774–1782
   PubMed Web of Science ®Google Scholar
• Albert D H, Tapang P, Magoc T J, Pease L J, Reuter D R, Wei R Q, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5: 995–1006
   PubMed Web of Science ®Google Scholar
• Nishiyama U, Yoshino T, Ozai M, Yoshioka R, Fujisawa M, Ogasawara Y, et al. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res 2006; 30: 1541–1546
   PubMed Web of Science ®Google Scholar
• Zeng Z, Samudio I J, Zhang W, Estrov Z, Pelicano H, Harris D, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006; 66: 3737–3746
   PubMed Web of Science ®Google Scholar
• Sohal J, Phan V T, Chan P V, Davis E M, Patel B, Kelly L M, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003; 101: 3188–3197
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes D E, Peng J, Garrett E N, Louie S G, Lee S H, Wiesmann M, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005; 11: 5281–5291
   PubMed Web of Science ®Google Scholar
• Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, et al. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia 2005; 19: 930–935
   PubMed Web of Science ®Google Scholar
• Gazit A, Yee K, Uecker A, Bohmer F D, Sjoblom T, Ostman A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003; 11: 2007–2018
   PubMed Web of Science ®Google Scholar
• Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003; 278: 32892–32898
   PubMed Web of Science ®Google Scholar
• Mahboobi S, Teller S, Pongratz H, Hufsky H, Sellmer A, Botzki A, et al. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem 2002; 45: 1002–1018
   PubMed Web of Science ®Google Scholar
• Pine P, Bahjat R, Chang B, Taylor V, Markovstov V, Hitoshi Y, et al. An Orally Bioavailable Inhibitor of FLT3 and Syk Kinases Prevents Tumor Growth in Subcutaneously Implanted Human Tumor Xenografts and Promotes Cell Death of FLT3 Mutant AML Cells. Blood 2005; 106: 74a
   Google Scholar
• Wilhelm S M, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109
   PubMed Web of Science ®Google Scholar
• Griessinger E, Imbert V, Lagadec P, Gonthier N, Dubreuil P, Romanelli A, et al. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007; 21: 877–885
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, et al. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res 2007; 13(15 Part 1)4575–4582
   PubMed Web of Science ®Google Scholar
• Shiotsu Y, Kiyoi H, Ozeki K, Umehara H, Shimizu M, Akinaga S, et al. KW-2449, a novel multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora, suppresses the growth of AML both in vitro and in vivo. Blood 2007; 118: 542a
   Google Scholar
• Giles F J, Stopeck A T, Silverman L R, Lancet J E, Cooper M A, Hannah A L, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795–801
   PubMed Web of Science ®Google Scholar
• O'Farrell A M, Foran J M, Fiedler W, Serve H, Paquette R L, Cooper M A, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465–5476
   PubMed Web of Science ®Google Scholar
• Smith B D, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669–3676
   PubMed Web of Science ®Google Scholar
• Stone R M, DeAngelo D J, Klimek V, Galinsky I, Estey E, Nimer S D, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60
   PubMed Web of Science ®Google Scholar
• DeAngelo D J, Stone R M, Heaney M L, Nimer S D, Paquette R L, Klisovic R B, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006; 108: 3674–3681
   PubMed Web of Science ®Google Scholar
• Lamers M B, Antson A A, Hubbard R E, Scott R K, Williams D H. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 1999; 285: 713–725
   PubMed Web of Science ®Google Scholar
• Bohmer F D, Karagyozov L, Uecker A, Serve H, Botzki A, Mahboobi S, et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem 2003; 278: 5148–5155
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann W G, Pellicena P, Schindler T, Veach D R, Miller W T, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243
   PubMed Web of Science ®Google Scholar
• Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003; 102: 646–651
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett A K, Littlewood T, Kell W J, Agrawal S, Chopra R, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108: 3262–3270
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999–2007
   PubMed Web of Science ®Google Scholar
• Avramis I A, Laug W E, Sausville E A, Avramis V I. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 2003; 52: 307–318
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F J, Kornblau S M, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396–4407
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460–466
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, Beelen D W, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469–1477
   PubMed Web of Science ®Google Scholar
• George D J, Dionne C A, Jani J, Angeles T, Murakata C, Lamb J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59: 2395–2401
   PubMed Web of Science ®Google Scholar
• Levis M, Brown P, Smith B D, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108: 3477–3483
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith B D, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004; 104: 1145–1150
   PubMed Web of Science ®Google Scholar
• Brown P, Levis M, McIntyre E, Griesemer M, Small D. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. Leukemia 2006; 20: 1368–1376
   PubMed Web of Science ®Google Scholar
• Mendel D B, Laird A D, Xin X, Louie S G, Christensen J G, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–337
   PubMed Web of Science ®Google Scholar
• Yee K W, Schittenhelm M, O'Farrell A M, Town A R, McGreevey L, Bainbridge T, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104: 4202–4209
   PubMed Web of Science ®Google Scholar
• Pandey A, Volkots D L, Seroogy J M, Rose J W, Yu J C, Lambing J L, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002; 45: 3772–3793
   PubMed Web of Science ®Google Scholar
• Griswold I J, Shen L J, La Rosee P, Demehri S, Heinrich M C, Braziel R M, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 2004; 104: 2912–2918
   PubMed Web of Science ®Google Scholar
• Mollgard L, Deneberg S, Nahi H, Bengtzen S, Jonsson-Videsater K, Fioretos T, et al. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemother Pharmacol, Epub ahead of print. 2007
   PubMed Web of Science ®Google Scholar
• Propper D J, McDonald A C, Man A, Thavasu P, Balkwill F, Braybrooke J P, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485–1492
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Vu H A, Akutsu M, Odgerel T, Izumi T, Tsunoda S, et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 2007; 21: 1005–1014
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis E M, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280: 35217–35227
   PubMed Web of Science ®Google Scholar
• Rosato R R, Almenara J A, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007; 67: 9490–9500
   PubMed Web of Science ®Google Scholar
• Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007; 92: 27–34
   PubMed Web of Science ®Google Scholar
• Kancha R K, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 2007; 35: 1522–1526
   PubMed Web of Science ®Google Scholar
• Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21: 439–445
   PubMed Web of Science ®Google Scholar
• Yu C, Friday B B, Lai J P, Yang L, Sarkaria J, Kay N E, et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 2006; 5: 2378–2387
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007; 13: 4280–4290
   PubMed Web of Science ®Google Scholar
• Shankar D B, Li J, Tapang P, Owen McCall J, Pease L J, Dai Y, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007; 109: 3400–3408
   PubMed Web of Science ®Google Scholar
• Zhou J, Pan M, Xie Z, Loh S L, Bi C, Tai Y C, et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008; 22: 138–146
   PubMed Web of Science ®Google Scholar
• Kappelmayer J, Udvardy M, Antal-Szalmas P. Pgp and FLT3: identification and modulation of two proteins that lead to chemotherapy resistance in acute myeloid leukemia. Curr Med Chem 2007; 14: 519–530
   PubMed Web of Science ®Google Scholar
• List A F, Kopecky K J, Willman C L, Head D R, Persons D L, Slovak M L, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212–3220
   PubMed Web of Science ®Google Scholar
• Perrotton T, Trompier D, Chang X B, Di Pietro A. Baubichon-Cortay H (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem 2007; 282: 31542–31548
   PubMed Web of Science ®Google Scholar
• Hunter H M, Pallis M, Seedhouse C H, Grundy M, Gray C, Russell N H. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol 2004; 127: 26–33
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000; 1482: 157–171
   PubMed Web of Science ®Google Scholar
• Kretz O, Weiss H M, Schumacher M M, Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2004; 58: 212–216
   PubMed Web of Science ®Google Scholar
• McKillop D, Hutchison M, Partridge E A, Bushby N, Cooper C M, Clarkson-Jones J A, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004; 34: 917–934
   PubMed Web of Science ®Google Scholar
• Chassany O, Urien S, Claudepierre P, Bastian G, Tillement J P. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 1996; 38: 571–573
   PubMed Web of Science ®Google Scholar
• Powell B L, White J C, Gregory B W, Brockschmidt J K, Rhinehardt-Clark A, Lyerly E S, et al. S-phase fraction is not correlated with nucleoside transport in acute myeloid leukemia cells. Leukemia 1991; 5: 598–601
   PubMed Web of Science ®Google Scholar
• Zhao M, Rudek M A, He P, Hafner F T, Radtke M, Wright J J, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 846: 1–7
   PubMed Web of Science ®Google Scholar
• Fleischman R A, Mintz B. Prevention of genetic anemias in mice by microinjection of normal hematopoietic stem cells into the fetal placenta. Proc Natl Acad Sci USA 1979; 76: 5736–5740
   PubMed Web of Science ®Google Scholar
• Amadori S, Arcese W, Isacchi G, Meloni G, Petti M C, Monarca B, et al. Mitoxantrone etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9: 1210–1214
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Levis M, Smith B D, Beran M, Baer M R, Erba H P, Cripe L, et al. A Randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood 2005; 106: 121a
   Web of Science ®Google Scholar
• Giles F, Schiffer C, Kantarjian H, Fischer J T, Paquette R, Pelov D, et al. Phase 1 study of PKC412, an oral FLT3 kinase inhibitor, in sequential and concomitant combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine (HDAra-C) consolidation in newly diagnosed patients with AML. Blood 2004; 104: 262a
   Google Scholar
• Stone R M, Fischer T, Paquette R, Gary Schiller C AS, Ehninger G, Cortes J, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood 2005; 106: 121a
   Google Scholar
• Deangelo D, Amrein P C, Kovacsovics T J, Klisovic R B, Powell B L, Cooper M A, et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 2006; 108: 51a
   Google Scholar
• Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O G, O'Farrell A M, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Andreef M, Faderl S, Wright J J, Zhang W, et al. Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML). J Clin Oncol 2007; 25: 7018
   Web of Science ®Google Scholar